Top

Published in:

01-03-2011

Future perspectives on neuroendocrine tumors

Authors: Daniel Castellano, Ramón Salazar, Eric Raymond

Published in: Cancer and Metastasis Reviews | Special Issue 1/2011

Abstract

In the last 30 years the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased substantially. This could be partly due to improvements in diagnostic imaging, which lead to the incidental diagnosis of asymptomatic cases. However, despite these improvements, patients typically experience long delays before they are diagnosed. In this review, we discuss both the limitations and advances in our understanding of the pathogenesis, molecular and cellular biology, diagnosis, classification, staging, and treatment of GEP-NETs in order to identify which factors could be contributing to the delay in diagnosis and timely treatment of these patients. Within this context, the results from the most relevant clinical trials the available targeted therapies for the treatment of GEP-NETs, such as the “RAD001 in Advanced Neuroendocrine Tumors,” will be discussed.

Modlin, I. M., Oberg, K., Chung, D. C., et al. (2008). Gastroenteropancreatic neuroendocrine tumours. The Lancet Oncology, 9(1), 61–72.PubMedCrossRef

Modlin, I. M., Lye, K. D., & Kidd, M. (2003). A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 97(4), 934–959.PubMedCrossRef

Modlin, I. M., Kidd, M., Latich, I., et al. (2005). Current status of gastrointestinal carcinoids. Gastroenterology, 128(6), 1717–1751.PubMedCrossRef

Rashid, N., Modlin, I., Tang, L., et al. (1997). The proliferative status of enterochromaffin-like (ECL) cells in the gastric mucosa. The plot thickens. Gastroenterology, 112(Suppl 4), A644.

Zikusoka, M. N., Kidd, M., Eick, G., et al. (2005). The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer, 104(11), 2292–2309.PubMedCrossRef

Yang, H. W., Kutok, J. L., Lee, N. H., et al. (2004). Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish. Cancer Research, 64(20), 7256–7262.PubMedCrossRef

Nilsson, O., Wangberg, B., Johansson, L., et al. (1992). Praomys (Mastomys) natalensis: a model for gastric carcinoid formation. The Yale Journal of Biology and Medicine, 65(6), 741–751. Discussion 827-9.PubMed

Fossmark, R., Martinsen, T. C., Bakkelund, K. E., et al. (2004). ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Research, 64(10), 3687–3693.PubMedCrossRef

Crabtree, J. S., Scacheri, P. C., Ward, J. M., et al. (2001). A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proceedings of the National Academy of Sciences of the United States of America, 98(3), 1118–1123.PubMedCrossRef

10.

Kidd, M., Modlin, I. M., & Tang, L. H. (1998). Gastrin and the enterochromaffin-like cell: an acid update. Digestive Surgery, 15(3), 209–217.PubMedCrossRef

11.

Parekh, D., Ishizuka, J., Townsend, C. M., Jr., et al. (1994). Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion. Pancreas, 9(1), 83–90.PubMedCrossRef

12.

Kolby, L., Bernhardt, P., Ahlman, H., et al. (2001). A transplantable human carcinoid as model for somatostatin receptor-mediated and amine transporter-mediated radionuclide uptake. The American Journal of Pathology, 158(2), 745–755.PubMedCrossRef

13.

Ellis, L. M., Samuel, S., & Sceusi, E. (2010). Varying opinions on the authenticity of a human midgut carcinoid cell line—letter. Clinical Cancer Research, 16(21), 5365–5366.PubMedCrossRef

14.

Thakker, R. V. (2006). Multiple endocrine neoplasia type I. In I. J. DeGroot & J. I. Jamesson (Eds.), Endocrinology (pp. 3509–3521). Philadelphia: Elseiver Saunders.

15.

Öberg, K. (2005). Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Current Opinion in Oncology, 17(4), 386–391.PubMedCrossRef

16.

Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004). The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews, 25(3), 458–511.PubMedCrossRef

17.

Kloppel, G., Perren, A., & Heitz, P. U. (2004). The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Annals of the New York Academy of Sciences, 1014, 13–27.PubMedCrossRef

18.

Koopmans, K. P., de Vries, E. G., Kema, I. P., et al. (2006). Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. The Lancet Oncology, 7(9), 728–734.PubMedCrossRef

19.

Koukouraki, S., Strauss, L. G., Georgoulias, V., et al. (2006). Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. European Journal of Nuclear Medicine and Molecular Imaging, 33(4), 460–466.PubMedCrossRef

20.

Orlefors, H., Sundin, A., Garske, U., et al. (2005). Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. The Journal of Clinical Endocrinology and Metabolism, 90(6), 3392–3400.PubMedCrossRef

21.

D’Onofrio, M., Zamboni, G., Faccioli, N., et al. (2007). Ultrasonography of the pancreas. 4. Contrast-enhanced imaging. Abdominal Imaging, 32(2), 171–181.PubMedCrossRef

22.

Hyslop, W. B., Balci, N. C., & Semelka, R. C. (2005). Future horizons in MR imaging. Magnetic Resonance Imaging Clinics of North America, 13(2), 211–224.PubMedCrossRef

23.

van Tuyl, S. A., van Noorden, J. T., Timmer, R., et al. (2006). Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointestinal Endoscopy, 64(1), 66–72.PubMedCrossRef

24.

Yamaguchi, T., Manabe, N., Tanaka, S., et al. (2005). Multiple carcinoid tumors of the ileum preoperatively diagnosed by enteroscopy with the double-balloon technique. Gastrointestinal Endoscopy, 62(2), 315–318.PubMedCrossRef

25.

Rindi, G., Kloppel, G., Alhman, H., et al. (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 449(4), 395–401.PubMedCrossRef

26.

Rindi, G., Kloppel, G., Couvelard, A., et al. (2007). TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv, 451(4), 757–762.PubMedCrossRef

27.

Öberg, K., Kvols, L., Caplin, M., et al. (2004). Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Annals of Oncology, 15(6), 966–973.PubMedCrossRef

28.

Öberg, K., & Jelic, S. (2009). Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annals of Oncology, 20(Suppl 4), 150–153.PubMed

29.

Benjegard, S. A., Forssell-Aronsson, E., Wangberg, B., et al. (2001). Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. European Journal of Nuclear Medicine, 28(10), 1456–1462.PubMedCrossRef

30.

Rinke, A., Muller, H. H., Schade-Brittinger, C., et al. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology, 27(28), 4656–4663.PubMedCrossRef

31.

Shojamanesh, H., Gibril, F., Louie, A., et al. (2002). Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer, 94(2), 331–343.PubMedCrossRef

32.

Panzuto, F., Di Fonzo, M., Iannicelli, E., et al. (2006). Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Annals of Oncology, 17(3), 461–466.PubMedCrossRef

33.

Kolby, L., Persson, G., Franzen, S., et al. (2003). Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery, 90(6), 687–693.PubMedCrossRef

34.

Kouvaraki, M. A., Ajani, J. A., Hoff, P., et al. (2004). Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology, 22(23), 4762–4771.PubMedCrossRef

35.

Hansel, D. E., Rahman, A., Hermans, J., et al. (2003). Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Modern Pathology, 16(7), 652–659.PubMedCrossRef

36.

Fjällskog, M. L., Hessman, O., Eriksson, B., et al. (2007). Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncológica, 46(6), 741–746.PubMedCrossRef

37.

Fjällskog, M. L., Lejonklou, M. H., Oberg, K. E., et al. (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clinical Cancer Research, 9(4), 1469–1473.PubMed

38.

Niccoli, P., Raoul, J., Bang, Y., et al. (2010). Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET). Journal of Clinical Oncology, 28(Suppl 15), 4000. Meeting abstracts.

39.

Pavel, M., Hainsworth, J.D., Baudin, E., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus plus octreotide LAR vs ersus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). In: 35th European Medical Oncology Society; 2010; Milan, Italy.

40.

Yao, J.C., Shah, M.H., Ito, T., et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). In: 35th European Society Medical Oncology; 2010; Milan, Italy.

41.

Hobday, T. J., Rubin, J., Holen, K., et al. (2007). MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. Journal of Clinical Oncology, 25(Suppl 18), 4504. Meeting abstracts.

42.

Castellano, D., Capdevilla, J., Salazar, R., et al. (2010). Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of Spanish Neuroendocrine Tumor Group (GETNE-0801). In: 35th European Society of Medical Oncology; 2010; Milan, Italy.

43.

Forrer, F., Valkema, R., Kwekkeboom, D. J., et al. (2007). Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Practice & Research. Clinical Endocrinology & Metabolism, 21(1), 111–129.CrossRef

44.

Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., et al. (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology, 26(13), 2124–2130.PubMedCrossRef

45.

van Essen, M., Krenning, E. P., Kam, B. L., et al. (2008). Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 35(4), 743–748.PubMedCrossRef

Title: Future perspectives on neuroendocrine tumors
Authors: Daniel Castellano
Ramón Salazar
Eric Raymond
Publication date: 01-03-2011
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue Special Issue 1/2011
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-011-9294-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

Somatostatin analogs for the treatment of neuroendocrine tumors

Current knowledge on diagnosis and staging of neuroendocrine tumors

Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Gastroenteropancreatic neuroendocrine tumors. Where are we now?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer